Sector News

GSK and Novartis complete deals to reshape both drugmakers

March 2, 2015
Life sciences
(Reuters) – GlaxoSmithKline and Novartis said on Monday they had completed a series of asset swaps worth more than $20 billion that will reshape both drugmakers.
 
GSK is forming a consumer health joint venture with Novartis, while at the same time buying the Swiss company’s vaccines business and divesting its cancer drugs portfolio to Novartis.
 
The two companies originally announced the transactions in April 2014 to bolster their best businesses and exit weaker ones as the drugs industry contends with healthcare spending cuts and increased generic competition.
 
GSK, which now plans to return 4 billion pounds ($6.2 billion) to shareholders, said it would provide an in-depth view of its prospects at an investor meeting to be held when it reports first-quarter results on May 6.
 
The complex deals are more significant for GSK than for Novartis, reflecting the fact that the British group’s market value is less than half that of its Swiss rival.
 
After holding off from providing financial guidance for this year when it reported annual results last month, GSK said it would provide 2015 earnings guidance and “profile the medium and long-term shape and opportunities” of the group on May 6.
 
The transactions come at a critical time for the British drugmaker, which will see new chairman Philip Hampton take over on May 7.
 
Hampton, who chairs Royal Bank of Scotland, takes the reins following a tough year at GSK, which was hit by a record fine of nearly $500 million in China for bribing doctors and has disappointed investors with weak lung drug sales.
 
The poor performance resulted in the bonus paid to Chief Executive Andrew Witty for 2014 being cut by 51 percent.
 
GSK is receiving net after tax proceeds from the Novartis transactions of $7.8 billion, the majority of which will be distributed to shareholders through a so-called B share scheme.
 
For Novartis, the asset swaps will boost the company’s already substantial presence in oncology and are expected to lift core margins immediately.
 
The Swiss drugmaker now has a portfolio of 22 oncology and haematology medicines, with the GSK deal providing new therapies in melanoma, kidney and blood cancers.
 
Novartis is paying $16 billion for GSK’s cancer drugs, although up to $1.5 billion of this may have to be returned to Novartis if GSK’s melanoma drugs fail to meet expectations. GSK believes the necessary conditions will be satisfied, after recent positive clinical trial results.
 
On top of the transactions with GSK, Novartis also sold its animal health business to Eli Lilly.
 
($1 = 0.6495 pounds) 
 
By Ben Hirschler (Editing by Louise Heavens and Mark Potter)

comments closed

Related News

October 2, 2022

GSK names Julie Brown, a 25-year AstraZeneca veteran, its first woman CFO

Life sciences

Five years ago, GSK made headlines when it hired Emma Walmsley to become the first woman to run a major pharmaceutical company. Now the Big Pharma has brought in another woman to control the company’s finances. Julie Brown will be GSK’s next chief financial officer. Brown, currently the chief operating and financial officer at fashion and beauty brand Burberry Group, is set to replace Iain Mackay.

October 2, 2022

Moderna creates new launch preparation role, poaches Novartis exec as manufacturing lead

Life sciences

Moderna created a new role responsible for “building out the company’s organization to support its growing pipeline.” Starting first thing 2023, Juan Andres, Moderna’s manufacturing head, will step into this new role under the title president of strategic partnerships and enterprise expansion, the company said Thursday.

October 2, 2022

Torrent Pharma to acquire Curatio for $245.16m

Life sciences

The latest takeover is anticipated to boost the presence of Torrent in the dermatology segment. Indian company Torrent Pharmaceuticals has signed a definitive agreement for the complete acquisition of Curatio Healthcare for $245.16m (Rs20bn).